BMY logo

Bristol-Myers Squibb Company

BMY
Healthcare|Drug Manufacturers - General|US
$62.14
-0.99 (-1.57%)
DCF Value
$239.82
Graham Number
$34.15
Cash / Share
$6.16
Next Earnings Report
Feb 4, 2027
EPS est. $1.56 · Revenue est. $12.66B
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (27)

Nov 2026
Est. completion
P3Alzheimer Disease
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Nov 2026
Est. completion
P4Healthy Volunteers
Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers
Dec 2026
Est. completion
P2Non Small Cell Lung Cancer
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
Dec 2026
Est. completion
P1Healthy Volunteers
A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
Dec 2026
Est. completion
P3Psychosis Associated With Alzheimer's Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Mar 2027
Est. completion
P1Chronic Lymphocytic Leukemia (CLL)
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
Jul 2027
Est. completion
P1Multiple Sclerosis
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Aug 2027
Est. completion
P1Solid Tumors
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Sep 2027
Est. completion
P2Cancer
The Drug Rediscovery Protocol (DRUP Trial)
Sep 2027
Est. completion
P3Psychosis Associated With Alzheimer's Disease
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Dec 2027
Est. completion
P3Relapsed or Refractory Multiple Myeloma (RRMM)
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Dec 2027
Est. completion
P2Lymphoma, Non-Hodgkin
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Jan 2028
Est. completion
P2Lymphoma
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
May 2028
Est. completion
P2Lupus Erythematosus, Systemic
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Aug 2028
Est. completion
P1Multiple Myeloma
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Aug 2028
Est. completion
P1Systemic Lupus Erythematosus
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Mar 2029
Est. completion
P3Schizophrenia
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Mar 2029
Est. completion
P1Refractory Autoimmune Diseases
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Mar 2030
Est. completion
P3Schizophrenia
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
May 2030
Est. completion
P1Relapsed and/or Refractory Multiple Myeloma
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026
National Register of Actionable Mutations
NCT05918666
Oct 2026
P3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034

Recent Press Releases

SEC Filings (69)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 29, 202610-QQuarterly reportDocumentIndex
Oct 29, 20268-KMaterial eventDocumentIndex
Aug 7, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 30, 202610-QQuarterly reportDocumentIndex
Jul 30, 20268-KMaterial eventDocumentIndex
Jun 5, 202611-KDocumentIndex
Jun 5, 202611-KDocumentIndex
Jun 5, 202611-KDocumentIndex
May 8, 2026S-8Employee stock planDocumentIndex
May 8, 20268-KMaterial eventDocumentIndex
Apr 30, 202610-QQuarterly reportDocumentIndex
Apr 30, 20268-KMaterial eventDocumentIndex
Apr 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 17, 2026DEFA14AProxy / shareholder voteDocumentIndex
Mar 27, 202615-12GDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 25, 2026ARSAnnual report to holdersDocumentIndex
Mar 25, 2026DEFA14AProxy / shareholder voteDocumentIndex
Mar 25, 2026DEF 14AProxy / shareholder voteDocumentIndex
Feb 11, 202610-KAnnual reportDocumentIndex
Feb 5, 20268-KMaterial eventDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Nov 18, 20258-KMaterial eventDocumentIndex
Nov 12, 2025CERTDocumentIndex
Nov 10, 20258-A12BDocumentIndex
Nov 10, 20258-KMaterial eventDocumentIndex
Nov 7, 2025424B5Offering prospectusDocumentIndex
Nov 5, 2025FWPDocumentIndex
Nov 3, 20258-KMaterial eventDocumentIndex
Nov 3, 2025424B2Offering prospectusDocumentIndex
Oct 31, 2025POSASRDocumentIndex
Oct 31, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Oct 30, 202510-QQuarterly reportDocumentIndex
Oct 30, 20258-KMaterial eventDocumentIndex
Jul 31, 202510-QQuarterly reportDocumentIndex
Jul 31, 20258-KMaterial eventDocumentIndex
Jul 25, 20258-KMaterial eventDocumentIndex
Jun 6, 202511-KDocumentIndex
Jun 6, 202511-KDocumentIndex
Jun 6, 202511-KDocumentIndex